Certified by Founder Lodge
The Invus Group
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $112,000,000
8 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Evergreen structure with over $8 billion under management. Offices in New York, Paris, and Hong Kong.
| Company | Date | Round | Raised |
|---|---|---|---|
 Neumora |
October, 17 ,2022 | Series B | $112,000,000 |
 Hemab Therapeutics |
February, 22 ,2023 | Series B | $135,000,000 |
 Bicara Therapeutics |
March, 07 ,2023 | Series B | $108,000,000 |
 Ring Therapeutics |
March, 10 ,2023 | Series C | $86,500,000 |
 Convergent Therapeutics, Inc. |
May, 04 ,2023 | Series A | $90,000,000 |
 ElevateBio |
May, 25 ,2023 | Series D | $401,000,000 |
 Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
 Engine Biosciences |
November, 01 ,2023 | Series A | $27,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
